Liver Fibrosis Progression in Chronic Liver Disease

Hôpital Pitié-Salpêtrière

LIVER FIBROSIS PREVALENCE IN FRANCE

At least one year follow up for fibrosis progression rate.

For Mortality and Morbidity one assessment at five years and one assessment at 10 years.

DRCD12

Professor Thierry POYNARD

Assistance Publique - Hôpitaux de Paris

Single blind, active treatment arm Lovaza, is the only fish oil supplement approved by the FDA. The Lovaza treatment group will take 4g of Lovaza daily for a minimum of 48 weeks.

Single blind, Placebo arm study drug will contain 994.0 mg of corn oil and 6mg of alpha tocopherol as an excipient in a soft gelatin capsule shell. Subjects will take 4g daily for a minimum of 48 weeks.

Non-Alcoholic Fatty Liver Disease

Approximately 50% of study subjects will be randomized to the active treatment arm -Lovaza. Subjects will be dosed with 4g of Lovaza gel capsules daily for a minimum of 48 weeks duration.

Lovaza

Approximately 50% of study subjects will be randomized to the placebo arm of this study. Placebo arm subjects will receive 4g of placebo gel caps daily for a minimum of 48 weeks duration.

placebo control

HMRI - Liver Center

Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease

Edward A. Mena, MD

Huntington Medical Research Institutes

GlaxoSmithKline

The intervention group involves dietary advice and monitoring. No drug or invasive procedure is involved.

The control group receives lifestyle advice from a clinician, and the clinical care is not inferior to current practice.

liver neoplasms/triglyceride

LIVER FIBROSIS PREVALENCE IN FRANCE

Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease

Low Glycemic Index Dietary Intervention Program in Nonalcoholic Fatty Liver Disease

Täydellisin lääketieteellinen tietokanta tieteen tukemana